Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Utilization of the Viracor® Assay in Directing Duration of Valganciclovir Prophylaxis in CMV High Risk Kidney Transplant Recipients

NCT05238220 is registered in ClinicalTrials.gov with Piedmont Healthcare as lead sponsor.

NCT NCT05238220
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05238220 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Utilization of the Viracor® Assay in Directing Duration of Valganciclovir Prophylaxis in CMV High Risk Kidney Transplant Recipients
Lead sponsor
Piedmont Healthcare
Phase
Observational
Overall status
Completed
Start date
January 4, 2021
Completion date
June 30, 2022
Enrollment
37 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

kidney transplant; complications